logo
Twitter
Discord
Email
logo
Stereotaxis, Inc.

Stereotaxis, Inc.

AMEX•STXS
CEO: Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2004-08-12
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Contact Information
710 North Tucker Boulevard, Suite 110, Saint Louis, MO, 63101, United States
314-678-6100
www.stereotaxis.com
Market Cap
$249.18M
P/E (TTM)
-10.4
12
Dividend Yield
--
52W High
$3.59
52W Low
$1.54
52W Range
55%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$7.46M-18.83%
4-Quarter Trend

EPS

-$0.07-7.77%
4-Quarter Trend

FCF

$0.00-100.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Months Revenue Growth Nine months total revenue reached $23.74M, increasing 15% driven by full year impact of acquired disposable sales.
Common Stockholder Loss Narrowed Net loss attributable to common stockholders narrowed to $17.07M, improving from $17.51M prior nine-month period.
Q3 Gross Margin Expansion Q3 Gross Margin rose to 55% from 45% last year, due to favorable shift in product mix towards disposables.
Financing Activities Provided Cash Secured $7.81M net cash from financing activities, primarily driven by July 2025 registered direct equity offering proceeds.

Risk Factors

Macroeconomic and Supply Chain Macro factors, supply chain issues, and inflation continue to pressure operations, potentially impacting product availability.
G&A Expense Driven Higher G&A expenses rose 13% to $13.7M, primarily driven by contingent consideration revaluation expense recognized in earnings.
Fluid Global Tariff Environment Fluid global tariff environment, especially US-China, could materially affect cost structure and gross margins if reinstated.
Future Capital Needs Risk Existing cash may not suffice; future financing may be required, potentially dilutive to current common stockholders.

Outlook

Advance Regulatory Adoption Plans to advance adoption of robotic systems in markets where regulatory clearance has been recently received or is pending.
Continued Operating Losses Expected Expect additional operating losses in remainder of 2025 while funding development, commercialization, and marketing initiatives.
APT Integration Focus Management focused on integrating APT business, minimizing complexity, and realizing strategic benefits post-acquisition completion.
ATM Program Funding Available $50.0M ATM Program remains available for working capital and accelerated commercialization pipeline funding needs.

Peer Comparison

Revenue (TTM)

NeoGenomics, Inc.NEO
$709.16M
+10.1%
Quanterix CorporationQTRX
$130.10M
-2.5%
Sanara MedTech Inc.SMTI
$101.90M
+30.6%

Gross Margin (Latest Quarter)

Sanara MedTech Inc.SMTI
92.9%
+2.1pp
Nyxoah S.A.NYXH
60.5%
-1.4pp
Exagen Inc.XGN
58.4%
+2.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NEO$331.49M-2.9-13.0%29.8%
QTRX$302.69M-3.1-30.5%9.0%
STXS$249.18M-10.4-249.4%12.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 2, 2026
|
EPS:-$0.06
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $7.46M-18.8%
    |
    EPS: $-0.07-7.8%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 13, 2025|
    Revenue: $8.80M+95.4%
    |
    EPS: $-0.05-35.3%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $7.47M+8.6%
    |
    EPS: $-0.07+20.5%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 14, 2025|
    Revenue: $26.92M+0.5%
    |
    EPS: $-0.30-11.1%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 14, 2024|
    Revenue: $9.20M+17.9%
    |
    EPS: $-0.08+9.7%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $4.50M-42.7%
    |
    EPS: $-0.07+19.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 15, 2024|
    Revenue: $6.88M+5.1%
    |
    EPS: $-0.06-9.7%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 8, 2024|
    Revenue: $26.77M-4.9%
    |
    EPS: $-0.27-3.8%
    Miss